Skin cancer screening aims to identify precancerous lesions and malignant skin tumors before they spread or advance. The procedure relies on targeted physical inspection, dermoscopy (a skin surface microscopy examination), and advanced imaging techniques. It belongs to diagnostic dermatology and preventive oncology. Main screening protocols target cutaneous melanoma (a skin cancer arising from pigment-producing cells), basal cell carcinoma (a slow-growing cancer from the basal layer of the skin), and squamous cell carcinoma (a malignancy arising from keratin-producing skin cells).

Skin cancer screening involves a systematic, head-to-toe examination of the skin. Patients remove clothing and wear a medical gown. The examiner systematically inspects all anatomical regions, including the scalp, face, ears, trunk, extremities, intertriginous folds, palmoplantar surfaces, and nail beds. A handheld dermatoscope is applied to suspicious pigmented or non-pigmented lesions to visualize epidermal and dermal structures. Suspicious sites are documented, measured, photographed, and scheduled for biopsy if diagnostic criteria for malignancy or atypia are met.

Evidence shows that professional skin examination detects malignancies at earlier, more treatable stages. Early identification of thin melanomas significantly increases long-term survival rates. Early detection of non-melanoma skin cancers allows for smaller surgical excisions, lower recurrence rates, and minimal cosmetic disfigurement.

Standard physical screening requires no direct physical recovery, allowing patients to resume normal daily activities immediately. If a lesion undergoes an incisional biopsy (removing a portion of a lesion) or an excisional biopsy (removing an entire abnormal lesion), localized tissue healing takes 7 to 14 days. Sutured wounds require standard site protection and simple hygiene precautions.

Skin cancer screening identifies precancerous conditions such as actinic keratosis (a rough, scaly skin patch caused by ultraviolet radiation) and dysplastic nevi (atypical moles with irregular features). It detects malignant conditions including cutaneous melanoma, basal cell carcinoma, squamous cell carcinoma, Merkel cell carcinoma (a rare, aggressive neuroendocrine skin cancer), and dermatofibrosarcoma protuberans (a rare soft tissue skin sarcoma).

Patients should prepare by conducting a preliminary self-examination and noting any growing, changing, bleeding, or non-healing spots. All nail polish and cosmetic face makeup should be removed prior to the examination to allow clear visual inspection of the nail beds and facial skin. Patients should leave hair loose without heavy styling products so the examiner can thoroughly inspect the scalp.

Visual examination carries no direct physical risks. Diagnostic biopsies performed during screening carry minor risks including localized discomfort, transient bleeding, minor infection (under 2%), hyperpigmentation, hypopigmentation, and localized scarring. There is also a small risk of psychological anxiety associated with diagnostic waiting periods or minor false-positive diagnostic findings.

The diagnostic journey begins with a clinical evaluation of risk factors and personal history. During the visit, a clinician performs a head-to-toe cutaneous evaluation using dermoscopy. Suspicious lesions are marked, photographed, or excised for histopathology (microscopic analysis of tissue). If a biopsy confirms malignancy, clinicians arrange staging and definitive treatment. Long-term follow-up schedules depend on overall clinical risk and pathology findings.